ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 41,800 shares, an increase of 305.8% from the December 15th total of 10,300 shares. Based on an average daily volume of 12,800 shares, the short-interest ratio is presently 3.3 days.

ProShares UltraShort Nasdaq Biotechnology Price Performance

NASDAQ BIS traded down $0.13 on Monday, hitting $18.25. 1,958 shares of the stock traded hands, compared to its average volume of 5,321. The business’s fifty day moving average is $16.82 and its two-hundred day moving average is $15.80. ProShares UltraShort Nasdaq Biotechnology has a 12 month low of $14.05 and a 12 month high of $21.10.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The business also recently declared a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were issued a $0.2064 dividend. This is a positive change from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.

Hedge Funds Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC acquired a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned approximately 4.78% of ProShares UltraShort Nasdaq Biotechnology as of its most recent filing with the Securities & Exchange Commission.

About ProShares UltraShort Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.